Vor Biopharma Inc - Asset Resilience Ratio
Vor Biopharma Inc (VOR) has an Asset Resilience Ratio of 12.65% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Vor Biopharma Inc (VOR) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Vor Biopharma Inc's Asset Resilience Ratio has changed over time. See VOR book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Vor Biopharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Vor Biopharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $58.72 Million | 12.65% |
| Total Liquid Assets | $58.72 Million | 12.65% |
Asset Resilience Insights
- Moderate Liquidity: Vor Biopharma Inc has 12.65% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Vor Biopharma Inc Industry Peers by Asset Resilience Ratio
Compare Vor Biopharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Vor Biopharma Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Vor Biopharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.65% | $58.72 Million | $464.13 Million | +5.67pp |
| 2024-12-31 | 6.98% | $9.98 Million | $142.89 Million | -43.45pp |
| 2023-12-31 | 50.43% | $105.81 Million | $209.83 Million | -7.21pp |
| 2022-12-31 | 57.63% | $172.54 Million | $299.37 Million | +21.50pp |
| 2021-12-31 | 36.14% | $87.67 Million | $242.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $75.91 Million | -- |
About Vor Biopharma Inc
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML… Read more